Xenetic Biosciences prices $4.5 million common stock offering

FRAMINGHAM, MA - Xenetic Biosciences, Inc. (NASDAQ:XBIO), a biopharmaceutical company focused on immuno-oncology technologies, has priced an underwritten offering of 735,000 shares of common stock at $6.12 per share, according to a press release statement issued Friday. The offering comes as the company’s stock has shown remarkable strength, posting a 190% return over the past week, according to InvestingPro data.

The offering is expected to generate approximately $4.5 million in gross proceeds before deducting underwriting discounts, commissions, and other estimated expenses. Canaccord Genuity is serving as the sole bookrunner for the transaction.

The company plans to use the net proceeds for working capital and general corporate purposes. The offering is expected to close on or about October 14, 2025, subject to customary closing conditions.

The offering is being conducted pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission on November 1, 2024.

Xenetic Biosciences is developing a DNase platform designed to improve outcomes of existing treatments by targeting neutrophil extracellular traps involved in cancer progression. The company is currently focused on advancing its systemic DNase program into clinical trials as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

In other recent news, Xenetic Biosciences, Inc. announced that its partner, PeriNess Ltd., has entered into a Clinical Study Agreement to investigate the use of DNase I in combination with anti-CD19 CAR T cells for treating patients with large B cell lymphoma. This exploratory study will be conducted at the Tel-Aviv Sourasky Medical Center, led by Dr. Ron Ram. Additionally, Xenetic has expanded its collaboration with The Scripps Research Institute to further develop its DNase-based oncology platform alongside CAR T-cell therapies. This expanded program will incorporate more models of lymphoma and leukemia to validate prior findings. Previous research at Scripps demonstrated that combining DNase I with CAR-T cells significantly reduced tumor burden and extended survival in lymphoma and metastatic melanoma models compared to CAR-T cell therapy alone. These developments highlight Xenetic’s ongoing efforts to enhance the efficacy of CAR T-cell therapies in oncology.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.